Coombes RC, Tovey H, Kilburn L, et al. A phase III multicentre double blind randomised trial of celecoxib versus placebo in primary breast cancer patients (REACT – Randomised EuropeAn celecoxib trial). SABCS 2017, GS3-03.
Boosten maakt lagere dosering olaparib mogelijk
apr 2024 | Borstkanker, Gynaecologische oncologie, Uro-oncologie